Genetic diagnosis in pediatric cardiomyopathy: Clinical application and research perspectives☆
Introduction
The Second International Conference on Cardiomyopathy in Children provided a forum for clinicians and scientists to discuss the current status of clinical care and research relevant to pediatric cardiomyopathy and identify critical questions and areas requiring additional research. There has been tremendous growth in the application of genetics to pediatric cardiomyopathy since the initial conference in 2006. The expanded availability of clinical molecular genetic testing for cardiomyopathy has significantly changed the landscape for clinical evaluation. Additional research is needed to better understand the genetic heterogeneity of cardiomyopathy in children, the implications of specific genotypes, the best approach to cardiac surveillance and genetic testing, and the utility of genotyping for individual risk stratification and, ultimately, more personalized therapy. This report summarizes the current status of genetic testing for pediatric cardiomyopathy and highlights some focus areas for future investigation.
Section snippets
The genetic basis of pediatric cardiomyopathy
Cardiomyopathies with known genetic causes can be broadly classified by pathophysiology into 5 types: hypertrophic (HCM), dilated (DCM), restrictive (RCM), left ventricular noncompaction (LVNC), and arrhythmogenic right ventricular cardiomyopathy (ARVC). The latter is infrequently identified in children. HCM, DCM, RCM, and LVNC all occur in childhood with a bimodal age distribution. One peak occurs in infancy (less than 1 year of age) and is characterized by the worst outcomes and broadest
Recommendations for clinical genetic evaluation and testing
A Heart Failure Society of America Practice Guideline was published by Hershberger et al. in 2009 to provide evidence based guidelines for cardiac surveillance and genetic testing in patients with possible familial or genetic causes of cardiomyopathy [11]. The guidelines address the level of evidence for clinical validity and clinical utility in making recommendations. Key components of the genetic recommendations include: 1) generate a 3 generation pedigree for all patients with cardiomyopathy
Availability of genetic testing
Clinical genetic testing should be performed in a laboratory that is accredited by Clinical Laboratory Improvement Amendment (CLIA) standards. Genetic testing for cardiomyopathy is changing rapidly and comprehensive molecular panels are currently available. Because of the heterogeneity of causes in pediatric cardiomyopathy, it is difficult to create an algorithm for genetic testing that is widely applicable, since testing should be guided by the differential for a specific patient. Clinical
The utility of genetic testing
There is a reason for optimism that genetic testing will improve the care of patients with cardiomyopathy [12]. Because testing has been clinically available for a relatively short time period, there are no published studies to compare outcomes in individuals that received testing versus those that did not. Furthermore, studies to examine the benefit to at risk family members are difficult to design and implement. The utility of genetic testing is an important topic that has received recent
Genomics and medicine
Isolated cardiomyopathy is most frequently the result of point mutations or small insertions or deletions in genes encoding sarcomeric or cytoskeletal proteins. Although recurrent mutations have been identified in multiple families, many disease causing mutations are private, occurring in a single family. This lack of a mutational “hot spot”, combined with the marked locus heterogeneity in cardiomyopathy, makes genetic testing challenging. Using traditional Sanger sequencing, there is
Conclusions
An understanding of the genetic basis of cardiomyopathy has come a long way from the initial description of MYH7 mutations in HCM. Genetic testing has transitioned from a research-only tool to an important component of the diagnostic evaluation of patients with cardiomyopathy and extension of care to at risk family members. The incorporation of genetic testing into clinical care is cost effective and allows for earlier detection and improved prevention of adverse events. Pediatric
References (17)
- et al.
Genetic evaluation of cardiomyopathy—a heart failure society of America practice guideline
J Card Fail
(2009) - et al.
Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy
J Am Coll Cardiol
(2009) - et al.
Keeping up with the next generation: massively parallel sequencing in clinical diagnostics
J Mol Diagn
(2008) - et al.
Massively parallel sequencing: the next big thing in genetic medicine
Am J Hum Genet
(2009) - et al.
Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry
Circulation
(2007) - et al.
Incidence, causes, and outcomes of dilated cardiomyopathy in children
JAMA
(2006) - et al.
Factors associated with establishing a causal diagnosis for children with cardiomyopathy
Pediatrics
(2006) - et al.
Shared genetic causes of cardiac hypertrophy in children and adults
N Engl J Med
(2008)
Cited by (10)
Cardiac Magnetic Resonance Imaging Features in Hypertrophic Cardiomyopathy Diagnosed at <21 Years of Age
2020, American Journal of CardiologyLessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group
2015, Cardiology in the YoungGenetic Evaluation of A Nation-Wide Dutch Pediatric DCM Cohort: The Use of Genetic Testing in Risk Stratification
2022, Circulation: Genomic and Precision MedicineImpact of Genetic Testing for Cardiomyopathy on Emotional Well-Being and Family Dynamics: A Study of Parents and Adolescents
2021, Circulation: Genomic and Precision MedicineBiallelic variants in PPP1R13L cause paediatric dilated cardiomyopathy
2020, Clinical GeneticsRetrospective analysis of clinical genetic testing in pediatric primary dilated cardiomyopathy: Testing outcomes and the effects of variant reclassification
2020, Journal of the American Heart Association
- ☆
Supported by the Children's Cardiomyopathy Foundation, Cincinnati Children's Hospital Translational Research Institute and NIH (HL087000-01A1). There are no relationships with industry.